EGFR Atypical Lung Cancer Signal Advances Toward Randomized Test

Company ORIC Pharmaceuticals Event Type Phase 1b data and Phase 3 plan Modality Oral small-molecule EGFR inhibitor Asset Enozertinib Target Atypical EGFR (PACC, L861Q) Disease Area First-line EGFR-atypical NSCLC Summary ORIC reported a high response rate for enozertinib in a small first-line EGFR-atypical non-small-cell lung…